Novocure Ltd Ord Sh (NVCR)

$11.76 -0.05 (-0.42%)
Market Cap 1.22B
Revenue (ttm) 605.22M
Net Income (ttm) -168.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27.86%
Debt to Equity Ratio 0.57
Volume 1,787,400
Avg Vol 1,704,058
Day's Range N/A - N/A
Shares Out 111.98M
Stochastic %K 46%
Beta 0.83
Analysts Strong Sell
Price Target $25.36

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic ca...

Industry: Medical Devices
Sector: Healthcare
Address:
Neuhofstrasse 21, Baar, Switzerland
Do_Your_Research
Do_Your_Research Dec. 4 at 7:17 PM
$NVCR anybody know why they went for metastatic for panova 4 instead of locally advanced? They know that more time on treatment is needed to see results. Seems like it would have been easier to show a large benefit in locally advanced.
1 · Reply
kellysmith1
kellysmith1 Dec. 4 at 6:14 PM
$NVCR CEO who knows what he is doing. Very excited for the future!!
1 · Reply
kellysmith1
kellysmith1 Dec. 4 at 6:07 PM
$NVCR but all you can…this one will rock and roll the next few months!! Buy and hold!
0 · Reply
scotofool
scotofool Dec. 4 at 12:19 PM
$NVCR can yuz hear the wankers coming? saying new ceo to turn around this save that. bollocks. saying to 40 watch. no tis proper cock-up. board riggered doyly more same. $NVCR trash, target 7.
0 · Reply
BostonNorth
BostonNorth Dec. 3 at 11:10 PM
$NVCR 🔥🥊
0 · Reply
Kyle7776
Kyle7776 Dec. 3 at 5:45 PM
$NVCR if both trident and panova hit could we go back to 40+ ?
1 · Reply
sck2
sck2 Dec. 3 at 12:23 PM
$NVCR 🕵️‍♂️
0 · Reply
sck2
sck2 Dec. 3 at 12:01 PM
$NVCR 🕵️‍♂️
0 · Reply
sck2
sck2 Dec. 2 at 9:57 PM
$NVCR 🕵️‍♂️💪🐂
0 · Reply
joed88
joed88 Dec. 2 at 7:20 PM
$NVCR Main Points - Doyle's - Bednar's Chat: CEO and Management Transitions Novocure is shifting from a single-product company to a multi-indication platform active in 16 countries. The board appointed Frank Leonard CEO to reinforce execution toward 2026, without changing the company’s declared strategy or targets. Leonard brings years of experience, including product development, significant cost reductions, and strengthening commercial/international operations, which has driven double-digit GBM growth outside the US in 2024. The CEO change is described as “management optimization”—realignment of responsibilities, capital allocation, and team structures to increase the likelihood of achieving already stated goals for the coming years.
7 · Reply
Latest News on NVCR
Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Dec 1, 2025, 7:00 AM EST - 3 days ago

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 8 days ago

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon

Nov 12, 2025, 10:00 AM EST - 22 days ago

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon

DHR

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Nov 12, 2025, 7:00 AM EST - 22 days ago

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 3:16 PM EDT - 5 weeks ago

NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript

Novocure Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 7:00 AM EDT - 5 weeks ago

Novocure Reports Third Quarter 2025 Financial Results

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum

Oct 17, 2025, 7:55 AM EDT - 6 weeks ago

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Oct 15, 2025, 7:00 AM EDT - 7 weeks ago

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Novocure to Report Third Quarter 2025 Financial Results

Oct 1, 2025, 7:00 AM EDT - 2 months ago

Novocure to Report Third Quarter 2025 Financial Results

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Sep 29, 2025, 4:30 PM EDT - 2 months ago

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sep 15, 2025, 7:00 AM EDT - 2 months ago

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 5:53 PM EDT - 3 months ago

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

Aug 29, 2025, 4:26 AM EDT - 3 months ago

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

LLY

Novocure Announces Upcoming Investor Events

Aug 28, 2025, 7:00 AM EDT - 3 months ago

Novocure Announces Upcoming Investor Events

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Aug 25, 2025, 7:00 AM EDT - 3 months ago

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Aug 20, 2025, 7:00 AM EDT - 3 months ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

NovoCure's Wearable Oncology Edge And Compelling Valuation

Jul 30, 2025, 12:47 AM EDT - 4 months ago

NovoCure's Wearable Oncology Edge And Compelling Valuation

Top 3 Health Care Stocks That May Explode In July

Jul 28, 2025, 6:52 AM EDT - 4 months ago

Top 3 Health Care Stocks That May Explode In July

HCA MOH

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

Jul 25, 2025, 4:49 PM EDT - 4 months ago

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

NovoCure Q2 Revenue Jumps 6 Percent

Jul 24, 2025, 6:37 PM EDT - 4 months ago

NovoCure Q2 Revenue Jumps 6 Percent

Novocure: Steady Ahead of Key Milestones

Jul 24, 2025, 9:21 AM EDT - 4 months ago

Novocure: Steady Ahead of Key Milestones

Novocure Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 7:00 AM EDT - 4 months ago

Novocure Reports Second Quarter 2025 Financial Results

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Jul 1, 2025, 7:00 AM EDT - 5 months ago

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Novocure to Report Second Quarter 2025 Financial Results

Jun 30, 2025, 7:00 AM EDT - 5 months ago

Novocure to Report Second Quarter 2025 Financial Results

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Jun 2, 2025, 2:05 PM EDT - 6 months ago

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 6 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

ZLAB

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 8:00 AM EDT - 6 months ago

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street

May 28, 2025, 6:57 AM EDT - 6 months ago

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street

NovoCure: Loading Up On Growth Catalysts

May 24, 2025, 3:12 AM EDT - 6 months ago

NovoCure: Loading Up On Growth Catalysts

Why NovoCure Stock Skyrocketed This Week

Apr 25, 2025, 1:21 PM EDT - 7 months ago

Why NovoCure Stock Skyrocketed This Week

Why NovoCure Stock Leaped 4% Higher Today

Apr 24, 2025, 7:03 PM EDT - 8 months ago

Why NovoCure Stock Leaped 4% Higher Today

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

Apr 24, 2025, 12:39 PM EDT - 8 months ago

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 10:34 AM EDT - 8 months ago

NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript

NovoCure Surpasses Q1 Expectations

Apr 24, 2025, 9:25 AM EDT - 8 months ago

NovoCure Surpasses Q1 Expectations

Novocure Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 8 months ago

Novocure Reports First Quarter 2025 Financial Results

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 10:16 AM EDT - 8 months ago

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Apr 22, 2025, 7:09 AM EDT - 8 months ago

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Why NovoCure Stock Was Withering on Wednesday

Apr 16, 2025, 3:43 PM EDT - 8 months ago

Why NovoCure Stock Was Withering on Wednesday

Novocure to Report First Quarter 2025 Financial Results

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Novocure to Report First Quarter 2025 Financial Results

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why

Mar 4, 2025, 7:00 PM EST - 9 months ago

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Mar 4, 2025, 7:00 AM EST - 9 months ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

NovoCure Q4 2024 Earnings: Strong And Growing Pipeline

Feb 28, 2025, 1:10 PM EST - 9 months ago

NovoCure Q4 2024 Earnings: Strong And Growing Pipeline

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth

Feb 28, 2025, 5:17 AM EST - 9 months ago

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth

NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript

Feb 27, 2025, 9:09 AM EST - 10 months ago

NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript

NovoCure Q4 EPS Misses, Revenue Matches

Feb 27, 2025, 8:53 AM EST - 10 months ago

NovoCure Q4 EPS Misses, Revenue Matches

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Feb 27, 2025, 7:00 AM EST - 10 months ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Jan 22, 2025, 4:00 AM EST - 11 months ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 13, 2025, 7:00 AM EST - 11 months ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 7:00 AM EST - 11 months ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Why NovoCure Stock Was Winning Big This Week

Dec 6, 2024, 8:32 AM EST - 1 year ago

Why NovoCure Stock Was Winning Big This Week

Do_Your_Research
Do_Your_Research Dec. 4 at 7:17 PM
$NVCR anybody know why they went for metastatic for panova 4 instead of locally advanced? They know that more time on treatment is needed to see results. Seems like it would have been easier to show a large benefit in locally advanced.
1 · Reply
kellysmith1
kellysmith1 Dec. 4 at 6:14 PM
$NVCR CEO who knows what he is doing. Very excited for the future!!
1 · Reply
kellysmith1
kellysmith1 Dec. 4 at 6:07 PM
$NVCR but all you can…this one will rock and roll the next few months!! Buy and hold!
0 · Reply
scotofool
scotofool Dec. 4 at 12:19 PM
$NVCR can yuz hear the wankers coming? saying new ceo to turn around this save that. bollocks. saying to 40 watch. no tis proper cock-up. board riggered doyly more same. $NVCR trash, target 7.
0 · Reply
BostonNorth
BostonNorth Dec. 3 at 11:10 PM
$NVCR 🔥🥊
0 · Reply
Kyle7776
Kyle7776 Dec. 3 at 5:45 PM
$NVCR if both trident and panova hit could we go back to 40+ ?
1 · Reply
sck2
sck2 Dec. 3 at 12:23 PM
$NVCR 🕵️‍♂️
0 · Reply
sck2
sck2 Dec. 3 at 12:01 PM
$NVCR 🕵️‍♂️
0 · Reply
sck2
sck2 Dec. 2 at 9:57 PM
$NVCR 🕵️‍♂️💪🐂
0 · Reply
joed88
joed88 Dec. 2 at 7:20 PM
$NVCR Main Points - Doyle's - Bednar's Chat: CEO and Management Transitions Novocure is shifting from a single-product company to a multi-indication platform active in 16 countries. The board appointed Frank Leonard CEO to reinforce execution toward 2026, without changing the company’s declared strategy or targets. Leonard brings years of experience, including product development, significant cost reductions, and strengthening commercial/international operations, which has driven double-digit GBM growth outside the US in 2024. The CEO change is described as “management optimization”—realignment of responsibilities, capital allocation, and team structures to increase the likelihood of achieving already stated goals for the coming years.
7 · Reply
kellysmith1
kellysmith1 Dec. 2 at 6:34 PM
$NVCR because they are idiots!!!
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 2 at 5:44 PM
$NVCR Why would shorts want to carry a short position into rollouts of Panc and Mets?
1 · Reply
kellysmith1
kellysmith1 Dec. 2 at 5:31 PM
$NVCR $20 by February
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 2 at 5:25 PM
$NVCR Added a nice slug of NVCR. I believe Franks succession was planned. With a high likelihood of Lung fail, why burn the best candidate to rollout Mets and Panc (Frank). Everyone questioned Ashley's appointment, now we can conclude it was probably strategy. Welcome to the execution of corporate white board exercises. Just my two shekels. GLTA
0 · Reply
sck2
sck2 Dec. 2 at 5:24 PM
$NVCR
0 · Reply
sck2
sck2 Dec. 2 at 5:02 PM
$NVCR ✅💪🐂
0 · Reply
sck2
sck2 Dec. 2 at 4:57 PM
$NVCR 🕵️‍♂️💪
0 · Reply
sck2
sck2 Dec. 2 at 4:36 PM
$NVCR brand new to this stock but now I do have a position here ... 🕵️‍♂️💪🐂
1 · Reply
RandomInvestor777
RandomInvestor777 Dec. 2 at 4:35 PM
$NVCR Basically said Ashley was garbo at execution and they think frank is a better executor
1 · Reply
kellysmith1
kellysmith1 Dec. 2 at 4:31 PM
$NVCR this is a good thing… see you at $14 before Christmas..
0 · Reply
scotofool
scotofool Dec. 2 at 5:18 AM
$NVCR @GordonGecko_was_THE_MAN proper pump_wanker now exposed, $NVCR trash, target 7
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 1 at 11:20 PM
$NVCR Ashley was never the long term solution but the position was not attractive enough to land real outside talent. They must realize....BoD, Soleus, et al...they get one more shot (panc and mets) and the next 18-24 months will be make or break. I can almost hear Soleus "dont F this up!!". Iblike the move but would still likento see David Hung actively involved.
1 · Reply